Volume 0 - Accepted Manuscripts                   Physiol Pharmacol 2021, 0 - Accepted Manuscripts: 0-0 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tahvilian R, Bagheri F. Topical formulation of tranilast improves hypertrophic scar in a rat model. Physiol Pharmacol. 2021;
URL: http://ppj.phypha.ir/article-1-1662-en.html
Abstract:   (52 Views)
Introduction: Hypertrophic scars are a dermal complication that may lead to considerable morbidity. There is an intense medical need for novel therapies for this disease. Tranilast is an anti-allergic drug used in the clinic for treatment of keloids and hypertrophic scars. In this study, we aimed to evaluate the effect of tranilast 0.5% topical formulation on hypertrophic scars resulted from burn injury in rats. Methods: Burn wounds were inflicted on the skin area of the backs of all rats, following that the scars are created, treatment started and continued for 28 days. Animals divided into two groups; the control scar group, which received placebo, and the treatment group that received tranilast. After this period, skin biopsies were collected from each group for the following analyses. The tissue samples were analyzed by H&E and Masson’s trichrome staining, and qRT-PCR. Results: Histologically, topical tranilast reduced hypertrophic scar signs as compared placebo. Tranilast treatment also resulted in a reduction type I and III collagen, Tgf-β1, Smad2 and Vegf, and increased Smad7 mRNA expression in the skin scar site. Conclusion: These findings revealed that topical 0.5% tranilast can be introduced as a topical agent in the treatment of hypertrophic scars.
Types of Manuscript: Original Research | Subject: Cellular and Molecular BioMedicine

Manuscript [PDF 894 KB]  (1 Download)
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.